• Fri frakt över 249 kr
  • •
  • Snabba leveranser
  • •
  • Billiga böcker
Kundservice

Du är på sajten för privatpersoner.

Företag, bibliotek eller offentlig verksamhet?

Du handlar på classic.bokus.com, där alla dina funktioner finns intakta.
Till classic.bokus.com
Bokus logotyp. Gå till startsidan.
  • Erbjudanden
  • Nyheter
  • Student
  • Topplistor
  • Barn & ungdom
  • Bokus Play
  • E-böcker
  • Pocketböcker
  • Spel & pussel

10% rabatt på allt med kod: NYSTART10 →

Sidfot

Mina sidor

    Hjälp

    • Kundservice
    • Vanliga frågor och svar
    • Frakt och leverans
    • Retur vid ångerrätt
    • Reklamera vara
    • Betalning
    • Köpvillkor
    • Allmänna villkor
    • Information om webbplatsens tillgänglighet

    Om Bokus

    • Om oss
    • Pressrum
    • För studenter
    • För företag
    • För bibliotek och offentlig verksamhet
    • För leverantörer
    • Hållbarhet

    Populärt

    • Aktuella erbjudanden
    • Presentkort
    • Studentlitteratur
    • Nya böcker
    • Topplistor
    • Signerade böcker
    • Engelska böcker

    Inspiration

    • Boktips
    • BookTok
    • Populära bokserier
    • Barnbokskaraktärer
    • Populära författare
    Logotyp för Bokus
    Följ oss på Facebook (extern länk)Följ oss på Instagram (extern länk)Följ oss på YouTube (extern länk)Följ oss på TikTok (extern länk)
    bokus @ CookiesAnpassa cookiesIntegritetspolicyKöpvillkor
    Till Citymail hemsida (extern länk)Till Budbee hemsida (extern länk)Till Postnord hemsida (extern länk)Till Schenker hemsida (extern länk)Till Early Bird hemsida (extern länk)Till Walleys hemsida (extern länk)
    1. Naturvetenskap och teknik
    2. Matematik och naturvetenskap
    3. Kemi

    Biomarkers in Drug Discovery and Development

    A Handbook of Practice, Application, and Strategy

    AvRamin Rahbari,Ramin Rahbari

    Inbunden, Engelska, 2020

    2 485 kr

    Beställningsvara. Skickas inom 5-8 vardagar. Fri frakt över 249 kr.

    Beskrivning

    This book continues the legacy of a well-established reference within the pharmaceutical industry – providing perspective, covering recent developments in technologies that have enabled the expanded use of biomarkers, and discussing biomarker characterization and validation and applications throughout drug discovery and development. Explains where proper use of biomarkers can substantively impact drug development timelines and costs, enable selection of better compounds and reduce late stage attrition, and facilitate personalized medicineHelps readers get a better understanding of biomarkers and how to use them, for example which are accepted by regulators and which still non-validated and exploratoryUpdates developments in genomic sequencing, and application of large data sets into pre-clinical and clinical testing; and adds new material on data mining, economics, and decision making, personal genetic tools, and wearable monitoringIncludes case studies of biomarkers that have helped and hindered decision makingReviews of the first edition:"If you are interested in biomarkers, and it is difficult to imagine anyone reading this who wouldn't be, then this book is for you." (ISSX) and "...provides a good introduction for those new to the area, and yet it can also serve as a detailed reference manual for those practically involved in biomarker implementation." (ChemMedChem)

    Produktinformation

    • Utgivningsdatum:2020-04-30
    • Mått:152 x 231 x 28 mm
    • Vikt:862 g
    • Format:Inbunden
    • Språk:Engelska
    • Antal sidor:608
    • Upplaga:2
    • Förlag:John Wiley & Sons Inc
    • ISBN:9781119187509

    Utforska kategorier

    • Kemi inom Naturvetenskap och teknik

    Mer om författaren

    RAMIN RAHBARI, MS, MBA, is an expert in biomarkers at Innovative Scientific Management and has previously held similar consulting and research positions at IBM, Cognizant and Pfizer. JONATHAN VAN NIEWAAL, MBA, is Technology Principal at Innovative Scientific Management and has held software development and technology delivery roles in the healthcare, financial services, and technology industries. MICHAEL R. BLEAVINS, PHD, DABT, is the founder of White Crow Innovation, LLC, a Michigan-based drug development consulting company, and cofounder of Michigan Technology and Research Institute.

    Innehållsförteckning

    • List of Contributors viiPreface xiiiPart I Biomarkers and Their Role in Drug Development 11 Biomarkers are Not New 3Ian Dews2 Biomarkers: Facing the Challenges at the Crossroads of Research and Health Care 15Gregory J. Downing3 Enabling Go/No Go Decisions 31J. Fred Pritchard and M. Lynn Pritchard4 Developing a Clinical Biomarker Method with External Resources: A Case Study 43Ross A. FredenburgPart II Identifying New Biomarkers: Technology Approaches 515 Imaging as a Localized Biomarker: Opportunities and Challenges 53Jonathan B. Moody, Philip S. Murphy, and Edward P. Ficaro6 Imaging for Early Clinical Drug Development: Integrating Imaging Science with Drug Research 89Philip S. Murphy, Mats Bergstrom, Jonathan B. Moody, and Edward P. Ficaro7 Circulating MicroRNAs as Biomarkers in Cardiovascular and Pulmonary Vascular Disease: Promises and Challenges 113Miranda K. Culley and Stephen Y. ChanPart III Characterization, Validation, and Utilization 1398 Characterization and Validation of Biomarkers in Drug Development: Regulatory Perspective 141Federico Goodsaid9 Fit-for-Purpose Method Validation and Assays for Biomarker Characterization to Support Drug Development 149Jean W. Lee, Yuling Wu, and Jin Wang10 Applying Statistics Appropriately for Your Biomarker Application 177Mary ZacourPart IV Biomarkers in Discovery and Preclinical Safety 21911 Qualification of Safety Biomarkers for Application to Early Drug Development 221William B. Mattes and Frank D. Sistare12 A Pathologist’s View of Drug and Biomarker Development 233Robert W. Dunstan13 Development of Serum Calcium and Phosphorus as Safety Biomarkers for Drug-Induced Systemic Mineralization: Case Study with the MEK Inhibitor PD0325901 255Alan P. Brown14 New Markers of Kidney Injury 281Sven A. BeushausenPart V Translating from Preclinical to Clinical and Back 30715 Biomarkers from Bench to Bedside and Back – Back-Translation of Clinical Studies to Preclinical Models 309Damian O'Connell, David Adler, Frank Kramer, and Matthias Ocker16 Translational Medicine – A Paradigm Shift in Modern Drug Discovery and Development: The Role of Biomarkers 333Giora Z. Feuerstein, Salvatore Alesci, Frank L.Walsh, J. Lynn Rutkowski, and Robert R. Ruffolo Jr.17 Clinical Validation and Biomarker Translation 347Ji-Young V. Kim, Raymond T. Ng, Robert Balshaw, Paul Keown, Robert McMaster, Bruce McManus, Karen Lam, and Scott J. Tebbutt18 Predicting and Assessing an Inflammatory Disease and Its Complications: Example from Rheumatoid Arthritis 365Christina Trollmo and Lars Klareskog19 Validating In Vitro Toxicity Biomarkers Against Clinical Endpoints 379Calvert Louden and Ruth A. RobertsPart VI Biomarkers in Clinical Trials 38920 Opportunities and Pitfalls Associated with Early Utilization of Biomarkers: A Case Study in Anticoagulant Development 391Kay A. Criswell21 Integrating Molecular Testing into Clinical Applications 409Anthony A. KilleenPart VII Big Data, Data Mining, and Biomarkers 42122 IT Supporting Biomarker-Enabled Drug Development 423Michael Hehenberger23 Identifying Biomarker Profiles Through the Epidemiologic Analysis of Big Health Care Data – Implications for Clinical Management and Clinical Trial Design: A Case Study in Anemia of Chronic Kidney Disease 447Gregory P. Fusco24 Computational Biology Approaches to Support Biomarker Discovery and Development 469Bin Li, Hyunjin Shin, William L. Trepicchio, and Andrew DornerPart VIII Lessons Learned: Practical Aspects of Biomarker Implementation 48525 Biomarkers in Pharmaceutical Development: The Essential Role of Project Management and Teamwork 487Lena King, Mallé Jurima-Romet, and Nita Ichhpurani26 Novel and Traditional Nonclinical Biomarker Utilization in the Estimation of Pharmaceutical Therapeutic Indices 505Bruce D. Car, Brian Gemzik, and William R. FosterPart IX Where are We Heading and What Do We Really Need? 51527 Ethics of Biomarkers: The Borders of Investigative Research, Informed Consent, and Patient Protection 517Sara Assadian, Michael Burgess, Breanne Crouch, Karen Lam, and Bruce McManus28 Anti-Unicorn Principle: Appropriate Biomarkers Don't Need to Be Rare or Hard to Find 537Michael R. Bleavins and Ramin Rahbari29 Translational Biomarker Imaging: Applications, Trends, and Successes Today and Tomorrow 553Patrick McConville and Deanne ListerIndex 585